AVAH · Aveanna Healthcare Holdings Inc.

The thesis

Aveanna Healthcare's earnings recovery is intact and the shares have rebounded to $13.18, but the case still turns on the third-quarter fiscal 2026 report on 12 November 2026. That report has to lift the fiscal 2026 adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) outlook above the greater-than-$365 million level set on 13 August 2026.

The company announced the report date on 22 October 2026: results before the market opens on Thursday 12 November 2026, with a call at 10:00 a.m. Eastern, per BioPharmaWatch's summary of the release. The shares closed at $13.18 on 26 October 2026, 8.3% below the $14.38 52-week high and 35.2% above the close three months earlier, per adjusted daily closes. The 14-day relative strength index (RSI) is 71.4, against 34.5 on 13 October 2026, when the close was $12.18.

The narrative is maturing: the August guidance raise is well known, analyst targets have moved up, and the next new information is the 12 November 2026 report. The recent rebound has put the shares into overbought territory ahead of that report, so the result carries more weight than it did two weeks ago.

Bullish and bearish views on Aveanna Healthcare Holdings Inc.

The bull case on Aveanna Healthcare Holdings Inc. (AVAH), in brief: The outlook was raised in August. The bear case: Insider and sponsor selling is persistent.

Bull case

• The outlook was raised in August. On 13 August 2026 Aveanna lifted fiscal 2026 revenue guidance to more than $2.68 billion and adjusted EBITDA guidance to more than $365 million. The prior ranges were $2.63–$2.65 billion and $338–$342 million, per the Q2 2026 results release.
• Revenue growth reached reported profit. For the quarter ended 4 July 2026, revenue was $670.483 million, up 13.7% year over year, and net income was $40.3 million, per the same release.
• The last quarter beat expectations. A summary of the 13 August 2026 results shows adjusted earnings per share of $0.22 against a $0.17 consensus estimate, and revenue of $670.5 million against $638.61 million expected.
• Analyst targets sit near the price. JPMorgan raised its target to $15 from $8 on 14 September 2026 while keeping a neutral rating, per Benzinga. MarketBeat's consensus target was $14.06 on 30 September 2026, and RBC Capital Markets carried the highest published target at $16 on 24 August 2026.
• Management cited new demand in California. Investing.com's summary of the 16 September 2026 Deutsche Bank Healthcare Summit reports management describing better growth, collections and margins from its preferred-payer strategy, plus a California reimbursement increase.

Bear case

• Insider and sponsor selling is persistent. MarketBeat counted insider sales of 48.6 million shares, about $558.5 million, over the 90 days to 30 September 2026. Director Erica G.
• Profit grew slower than revenue. Adjusted EBITDA rose 8.0% year over year in the quarter ended 4 July 2026 against 13.7% revenue growth, for a 14.2% margin, per the 13 August 2026 release.
• Debt is large and floating-rate. Total debt was $1,483.4 million against $97.2 million of cash at 4 July 2026, and the $520 million interest-rate swap expired in June 2026, per the Q2 2026 release and company disclosures.
• Medicaid funds most of the revenue. Investing.com's summary of the 16 September 2026 summit describes the company as more than 80% Medicaid-driven, which ties earnings to state reimbursement decisions.
• The shares are overbought into the report. The 14-day RSI was 71.4 on 26 October 2026. Benzinga flagged Aveanna among health care stocks with RSI readings above 70 on 10 September 2026, and the shares gave back ground in the weeks after.

Price setup

The adjusted daily close was $13.18 on 26 October 2026. The 52-week high is $14.38, and the $11.75 August 2026 secondary-offering price sits below the market. The offering consisted entirely of shares from selling stockholders, so the company received no proceeds.

On 30 September 2026 MarketBeat put the 50-day moving average at $12.08 and the 200-day at $9.05. The close of $13.18 is above both, and the 3-month gain of 35.2% is large. Crowding evidence observable today: an RSI above 70, an earnings date 16 days away, and heavy insider and sponsor selling over the prior 90 days. The sample of one rebound after one pullback is too small to say whether the rise since 13 October 2026 is a new trend.

If the report confirms a higher outlook, the $14.38 high is the next reference point. If the outlook is unchanged, the August offering price becomes the nearest reference for where selling stockholders sold.

Catalysts, next 30 days

• 12 November 2026, before the market opens: Third-quarter fiscal 2026 results, with a call at 10:00 a.m. Eastern. The report settles whether adjusted EBITDA guidance rises above $365 million and whether the margin holds at or above the 14.2% reported for the quarter ended 4 July 2026.
• Through 12 November 2026: New SEC Form 4 or Form 144 filings from directors or the former sponsor would show whether selling continues into the rebound.

What would change the view

The case breaks if the 12 November 2026 report leaves the greater-than-$365 million fiscal 2026 adjusted EBITDA outlook unchanged or lowers it, or if the third-quarter adjusted EBITDA margin falls below 14.2%. A cut tied to a Medicaid reimbursement change in a core state would be a second break.

On price, a weekly close below $11.75, the August 2026 secondary-offering price, would remove the level where the last large block of shares changed hands.

What it trades with

Aveanna trades with home-health and pediatric-care providers and with the wider managed-care and health-services group, where Medicaid funding decisions move the shares together. Interest-rate moves matter more here than for most peers because the debt is floating-rate and the hedge has expired. The shares have also traded with the broader momentum factor: Benzinga's 10 September 2026 overbought list grouped Aveanna with Inspire Medical and Cybin, whose businesses are unrelated.